A company’s plan to edit the genomes of human embryos worries some researchers — but it might reflect the changing attitudes ...

Two days after Intellia voluntarily paused dosing due to safety concerns, the regulator stepped in with an official hold that ...

Vinay Prasad, chief of the FDA’s Center for Biologics Evaluation and Research, is planning to publish a paper this month to ...

In a world first, a bespoke gene-editing therapy benefitted one child. Now reseachers plan to launch a clinical trial of the ...

A top US regulator plans to unveil a faster approach to approving custom gene-editing treatments, a move designed to unleash a wave of industry investment that will yield cures for patients with rare ...

Intellia Therapeutics said it is pausing two late-stage CRISPR gene-editing trials after a patient in one study was hospitalized with liver damage.

Both CRSP and NTLA are advancing in vivo gene editing therapies targeting large markets, with financial stability supporting ...

Intellia earlier this year reported a similar grade 4 liver enzyme elevation associated with the gene therapy nexiguran ...

Intellia Therapeutics will find it challenging to survive now that its CRISPR gene-editing treatment has been tied to severe, ...

In a first for adults in Singapore, scientists are conducting gene editing trials on heart patients to correct defects at ...

Stanford researchers and their collaborators have revealed a new device that could change the way scientists conduct gene-editing experiments. The device, CRISPR-GPT, is an artificial intelligence lab ...

The goal of gene therapy is to permanently cure hereditary diseases. One of the most promising technologies for this is the ...